First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

Summary

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.

Timeline

Start

2025-03-27

Primary completion

2028-02-25

Completion

2028-07-25

Drugs

Indications